Kirschbrown, Whitney P; Wang, Bei; Nijem, Ihsan; Ohtsu, Atsushi; Hoff, Paulo Marcelo Gehm 
; Shah, Manish A; Shen, Lin; Kang, Yoon-Koo; Alsina, Maria; Girish, Sandhya; Garg, Amit
Source: Cancer chemotherapy and pharmacology. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, NEOPLASIAS GÁSTRICAS, METÁSTASE NEOPLÁSICA, QUIMIOTERAPIA COMBINADA, RECEPTORES DE SUPERFÍCIE CELULAR, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KIRSCHBROWN, Whitney P et al. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. Cancer chemotherapy and pharmacology, v. 84, n. 3, p. 539-550, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00280-019-03871-w. Acesso em: 17 nov. 2024.APA
Kirschbrown, W. P., Wang, B., Nijem, I., Ohtsu, A., Hoff, P. M. G., Shah, M. A., et al. (2019). Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. Cancer chemotherapy and pharmacology, 84( 3), 539-550. doi:10.1007/s00280-019-03871-wNLM
Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PMG, Shah MA, Shen L, Kang Y-K, Alsina M, Girish S, Garg A. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer [Internet]. Cancer chemotherapy and pharmacology. 2019 ; 84( 3): 539-550.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s00280-019-03871-wVancouver
Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PMG, Shah MA, Shen L, Kang Y-K, Alsina M, Girish S, Garg A. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer [Internet]. Cancer chemotherapy and pharmacology. 2019 ; 84( 3): 539-550.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s00280-019-03871-w
